[Correspondence] Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update

Stefanie D Krens1 and colleagues have addressed and provided an overview of the topic of dose recommendations in patients with renal or hepatic impairment starting anticancer therapy in their 2019 review. Still, an increasing number of patients with cancer have impaired renal and hepatic function due to ageing and comorbidities.2,3 With the rise in cancer incidence and the rapidly expanding number of systemic treatment options, one might foresee that dose adjustments in these patients could be required more frequently based on one’s renal or hepatic function.